STS

Mass Megawatts Wind Power, Inc. Announces Changing the Name of the Company to Mass Megawatts, Inc.

Retrieved on: 
Monday, June 26, 2023

WORCESTER, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Mass Megawatts Wind Power, Inc. (OTC:MMMW) www.massmegawatts.com today announces that the Company has nearly completed the process of changing the name of the Company from Mass Megawatts Wind Power, Inc. to Mass Megawatts, Inc.

Key Points: 
  • WORCESTER, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Mass Megawatts Wind Power, Inc. (OTC:MMMW) www.massmegawatts.com today announces that the Company has nearly completed the process of changing the name of the Company from Mass Megawatts Wind Power, Inc. to Mass Megawatts, Inc.
  • The Company will announce the date of the name change as soon as the Company completes the regulatory process.
  • Since most of our business has been involved with solar energy related activity since 2014, we believe that changing our name from Mass Megawatts Wind Power, Inc. to Mass Megawatts, Inc. is a reasonable action to reflect the business of the Company more accurately in recent years.
  • At the same time, the Company will continue with wind power activities while most of our business will be primarily with solar power.

Avelo Airlines Doubles Down on Vegas with New Base

Retrieved on: 
Thursday, June 22, 2023

LAS will be Avelo's sixth U.S. base

Key Points: 
  • LAS will be Avelo's sixth U.S. base
    LAS VEGAS, June 22, 2023 /PRNewswire/ -- Avelo Airlines announced today it will open its sixth U.S. base in Las Vegas this September.
  • Avelo Airlines Founder, Chairman and CEO Andrew Levy said, "As the Entertainment Capital of the World, Las Vegas is a winning bet for our sixth U.S. base.
  • We are excited about the exclusive nonstop access to Vegas Avelo's new base will offer our Customers from these five communities and more in the future.
  • The new flights, destinations and jobs our new base will enable is a winning hand for Las Vegas, Avelo and, most importantly, our Customers."

Silvus Awarded $5.5 Million Contract By U.S. Army For StreamCaster PRISM Precision Integrated Sectorized MIMO - Antenna Radio Systems

Retrieved on: 
Tuesday, June 20, 2023

LOS ANGELES, June 20, 2023 /PRNewswire/ -- Silvus Technologies, Inc. ("Silvus"), a global leader of advanced wireless networking communication systems, today announced that the U.S. Army has awarded Silvus a $5.5 Million contract for StreamCaster PRISM Precision Integrated Sectorized MIMO in support of the Sustainment Transport System Line-of-Sight Program (STS LOS). The initial task order from the U.S. Army includes StreamCaster PRISM Antenna Radio systems, training, spares, and integrated logistical support.

Key Points: 
  • LOS ANGELES, June 20, 2023 /PRNewswire/ -- Silvus Technologies, Inc. ("Silvus"), a global leader of advanced wireless networking communication systems, today announced that the U.S. Army has awarded Silvus a $5.5 Million contract for StreamCaster PRISM Precision Integrated Sectorized MIMO in support of the Sustainment Transport System Line-of-Sight Program (STS LOS).
  • The initial task order from the U.S. Army includes StreamCaster PRISM Antenna Radio systems, training, spares, and integrated logistical support.
  • In addition, all StreamCaster PRISM systems acquired by the Army will include Silvus' proprietary Mobile Networked MIMO (MN-MIMO) waveform with Spectrum Dominance features to enable operations in congested and contested environments.
  • "StreamCaster PRISM exemplifies Silvus' commitment to delivering on the Army's unified network modernization efforts, providing high bandwidth connectivity for line-of-sight logistics data exchange," said Mike Kell, Silvus Director of Army Strategic Programs.

Thermosome Announces Participation in IMAGIO Consortium to Improve Cancer Treatment

Retrieved on: 
Tuesday, June 20, 2023

Consortium aims to improve clinical outcomes through less invasive treatments for lung cancer, liver cancer and soft tissue sarcomas

Key Points: 
  • Consortium aims to improve clinical outcomes through less invasive treatments for lung cancer, liver cancer and soft tissue sarcomas
    Munich, Germany – June 20, 2023 – Thermosome, a drug development company specializing in targeted tumor therapies, today announced its participation in the IMAGIO consortium set out to develop innovations in interventional oncology focused on lung cancer, liver cancer and soft tissue sarcomas (STS).
  • "We are delighted to be part of the IMAGIO consortium, and we look forward to expanding our collaboration with the University Hospital of Cologne," said Dr. Pascal Schweizer, co-founder and CEO/CFO of Thermosome.
  • IMAGIO will build on this project and also consider the results of our ongoing Phase I trial of THE001, which was initiated earlier this year."
  • I strongly believe that this project will nicely integrate these components, paving the way for broader clinical use of this approach.”

Mass Megawatts Announces Breakthrough for Lowest-Cost Energy Production with More Details on June 29

Retrieved on: 
Friday, June 16, 2023

The Concentrated Solar Tracking System (CST) is designed to dramatically lower the cost of energy production for consumers.

Key Points: 
  • The Concentrated Solar Tracking System (CST) is designed to dramatically lower the cost of energy production for consumers.
  • The CST provides an innovative solar tracking platform that utilizes low-cost reflectors directed at Stirling engines mounted at the center of its platform.
  • The CST is projected to substantially reduce power-generation costs by up to 56% as compared to traditional solar power installations.
  • With no expensive raw materials or complex engineering requirements, mass production would reduce the cost much greater than 56 percent as compared to traditional solar power installations.

Eminence Capital Sends Open Letter to Entain Board of Directors Following Value Destructive Equity Offering

Retrieved on: 
Friday, June 16, 2023

Eminence Capital, LP (“Eminence,” “we” or “us”) today issued the following open letter to Entain plc’s (LSE: ENT) (“Entain” or the “Company”) Board of Directors (the “Board”) following the Company’s recently announced proposed acquisition of STS Holdings and concurrent equity offering.

Key Points: 
  • Eminence Capital, LP (“Eminence,” “we” or “us”) today issued the following open letter to Entain plc’s (LSE: ENT) (“Entain” or the “Company”) Board of Directors (the “Board”) following the Company’s recently announced proposed acquisition of STS Holdings and concurrent equity offering.
  • To the Board of Directors of Entain plc:
    Eminence currently has an economic interest (physical shares and total return swaps) of approximately 13.2 million shares of Entain, representing approximately 2.1% of the shares outstanding.
  • The market reaction to this equity offering should be a wake-up call to Entain’s tone deaf Board and management team.
  • Eminence will continue to make its voice heard in an effort to ensure Entain’s Board and management do not make any further value destructive decisions.

Mae’n bryd i ni ailfeddwl beth yw gwyddoniaeth dinasyddion

Retrieved on: 
Saturday, June 10, 2023

Mae gwyddoniaeth dinasyddion yn ddull poblogaidd o gasglu data ar gyfer gwyddonwyr naturiol a chymdeithasol, ac mae nifer y prosiectau a'r cyhoeddiadau a gynhyrchir yn tyfu o flwyddyn i flwyddyn.

Key Points: 
  • Mae gwyddoniaeth dinasyddion yn ddull poblogaidd o gasglu data ar gyfer gwyddonwyr naturiol a chymdeithasol, ac mae nifer y prosiectau a'r cyhoeddiadau a gynhyrchir yn tyfu o flwyddyn i flwyddyn.
  • Mae prosiect gwyddoniaeth dinasyddion nodweddiadol yn defnyddio gwirfoddolwyr i gasglu data a fyddai, fel arall, yn anfforddiadwy neu'n anhygyrch.

Beth yw gwyddoniaeth?

    • Rydym yn gweithio o fewn astudiaethau gwyddoniaeth a thechnoleg (STS) sy'n edrych ar y modd y cawsant eu creu a'u datblygu.
    • Rydym yn astudio’r modd y mae gwyddoniaeth a thechnoleg yn eistedd o fewn eu cyd-destunau hanesyddol, diwylliannol a chymdeithasol.
    • Hynny yw, mae'r modd yr ydym yn gweld ac yn dehongli'r byd o'n cwmpas yn dibynnu ar argaeledd offer gwyddonol megis microsgopau, synwyryddion amgylcheddol, ac ati.
    • Felly, os yw gwyddoniaeth yn tueddu i atgynhyrchu braint a phersbectif grwpiau elitaidd, yna mae gwyddoniaeth dinasyddion yn cynnig y posibilrwydd o wyddoniaeth i'r bobl, gan y bobl.

Y Barri

    • Mae'n ymwneud â gwaith bio-màs yng nghanol y dref, y mae ymgyrchwyr amgylcheddol lleol yn dadlau y dylid ei ddymchwel.
    • Edrychon ar y modd y mae aelodau Grŵp Gwyddoniaeth Dinasyddion y Barri (BCSG) wedi ceisio atal y gwaith bio-màs rhag gweithredu.
    • Maent wedi treulio 15 mlynedd yn craffu ar y cyfreithiau a'r rheoliadau sydd wedi arwain at y penderfyniadau cynllunio a thrwyddedu hyd yn hyn.
    • Ein dadl yw bod y gwaith y maent wedi'i wneud hyd yn hyn yn rhagflaenydd hanfodol i waith casglu data mwy ffurfiol dan arweiniad y gymuned.

Mass Megawatts to Announce Best Patent Pending Technology in Company’s History Utilizing Concentrated Solar Power for Potential Project Paybacks of Less Than Three Years on June 29

Retrieved on: 
Tuesday, June 6, 2023

In combination with its solar tracker, new patent pending Stirling engine, and new patent pending solar concentration techniques, Mass Megawatts believes that the time is right to accelerate the renewable energy revolution that is getting stronger every day.

Key Points: 
  • In combination with its solar tracker, new patent pending Stirling engine, and new patent pending solar concentration techniques, Mass Megawatts believes that the time is right to accelerate the renewable energy revolution that is getting stronger every day.
  • The new technology will be the company’s most important application of its previously disclosed patent pending solar tracker which can produce 35 percent more solar power for less than ten percent additional cost.
  • A video on the home page of www.massmegawatts.com summarizes the previously disclosed patent pending solar tracker.
  • The company’s Solar Tracking System (STS) in itself is a new patent pending product that significantly reduces the payback period for solar power investments.

Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Retrieved on: 
Saturday, June 3, 2023

SAN CARLOS, Calif., June 03, 2023 (GLOBE NEWSWIRE) -- Apexigen, Inc. (Nasdaq: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the presentation of new data from a Phase 2 investigator-sponsored trial in collaboration with Columbia University, evaluating sotigalimab (sotiga), Apexigen’s agonist antibody targeting CD40, in combination with standard-of-care doxorubicin (dox), in patients with advanced soft tissue sarcoma (STS). These data were presented in a poster presentation on June 3, 2023 at the ASCO Annual Meeting being held both virtually and in person in Chicago, IL.

Key Points: 
  • These data were presented in a poster presentation on June 3, 2023 at the ASCO Annual Meeting being held both virtually and in person in Chicago, IL.
  • The interim ORR observed in the trial is comparable to the ORR of single-agent doxorubicin in the STS population.
  • Durable objective responses and stable disease have been observed beyond what might be expected from single-agent doxorubicin.
  • Title: A phase 2 trial with a safety lead-in to evaluate the addition of sotigalimab, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma

Decibel Therapeutics to Present DB-020 Phase 1b Clinical Trial Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Retrieved on: 
Thursday, June 1, 2023

BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois, June 2-6, 2023.

Key Points: 
  • BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois, June 2-6, 2023.
  • The Company will present a poster summarizing data from the interim analysis of the Phase 1b clinical trial of DB-020, a novel, proprietary formulation of sodium thiosulfate (STS) designed to protect against hearing loss in cancer patients receiving cisplatin chemotherapy.
  • “Hearing loss and tinnitus are significant, often debilitating sequelae of cisplatin-induced ototoxicity, for which there are currently no approved therapies.
  • Additional information about the clinical trial can be found at clinicaltrials.gov .